Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitroMarie Fortin(Jazz Pharmaceuticals (United States)), D. Manca(Jazz Pharmaceuticals (United States))Scientific ReportsNovember 29, 202310.1038/s41598-023-47293-4Cited by 10SaveCiteExport RISWatch citationsRelated PapersBeyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)|Clinical Pharmacology & Therapeutics|2024|15